Acute antidepressant response to fluoxetine and sertraline in psychiatric outpatients with psychomotor agitation

被引:8
作者
Flament, MF
Lane, R
机构
[1] Hop La Pitie Salpetriere, INSERM, CNRS, UMR 7593, F-75013 Paris, France
[2] Pfizer Inc, New York, NY USA
关键词
depression; sertraline; fluoxetine; psychomotor agitation;
D O I
10.1080/136515001300374830
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
INTRODUCTION: Sertraline and fluoxetine have different pharmacologic and pharmacokinetic profiles, which may be of clinical relevance in the determination of treatment response in different subtypes of depression. OBJECTIVES To analyse the efficacy of sertraline and fluoxetine in a subgroup of 78 patients with evidence of significant psychomotor agitation (HAM-D item 8 less than or equal to 1 and HAM-D item 9 greater than or equal to 2 at study entry) in a 6-week study comparing sertraline (50-100 mg/day) and fluoxetine (20-40 mg/ day) for the treatment of major depression in 286 psychiatric outpatients. RESULTS: The proportion of patients with psychomotor agitation responding (greater than or equal to 50% reduction HAM-D score) at last visit was significantly (P < 0.05) higher in the sertraline group than in the fluoxetine group (62% vs 39%, respectively). Most of the secondary efficacy parameters showed significantly (P < 0.05) greater improvement in the sertraline treatment group at last visit: HAM-D less than or equal to 8, HAM-D total score, HAM-D anxiety/ somatization factor, HAM-D weight factor, HAM-A total score, CGI-S, Raskin Depression score, and Covi Anxiety score. CONCLUSION: The findings of this retrospective data analysis suggest that fluoxetine may be a less efficacious antidepressant than sertraline in patients with psychomotor agitation.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 31 条
[1]   PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF SIGMA-SITES IN DTG-INDUCED CONTRALATERAL CIRCLING IN RATS [J].
BASTIANETTO, S ;
PERRAULT, G ;
SANGER, DJ .
NEUROPHARMACOLOGY, 1995, 34 (01) :107-114
[2]  
BEASLEY CM, 1991, J CLIN PSYCHOPHARM, V11, P166
[3]  
BENNIE EH, 1995, J CLIN PSYCHIAT, V56, P229
[4]   MODIFICATION OF THE N-METHYL-D-ASPARTATE RESPONSE BY ANTIDEPRESSANT SIGMA-RECEPTOR LIGANDS [J].
BERGERON, R ;
DEBONNEL, G ;
DEMONTIGNY, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 240 (2-3) :319-323
[5]   BLOCKADE BY NEWLY-DEVELOPED ANTIDEPRESSANTS OF BIOGENIC-AMINE UPTAKE INTO RAT-BRAIN SYNAPTOSOMES [J].
BOLDENWATSON, C ;
RICHELSON, E .
LIFE SCIENCES, 1993, 52 (12) :1023-1029
[6]   Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life [J].
Bondareff, W ;
Alpert, M ;
Friedhoff, AJ ;
Richter, EM ;
Clary, CM ;
Batzar, E .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (05) :729-736
[7]   INTERPERSONAL SENSITIVITY AND THE ONE-YEAR OUTCOME OF A DEPRESSIVE EPISODE [J].
BOYCE, P ;
HICKIE, I ;
PARKER, G ;
MITCHELL, P ;
WILHELM, K ;
BRODATY, H .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1992, 26 (02) :156-161
[8]   THE SYMPTOMS OF MAJOR DEPRESSION [J].
BUCHWALD, AM ;
RUDICKDAVIS, D .
JOURNAL OF ABNORMAL PSYCHOLOGY, 1993, 102 (02) :197-205
[9]  
CLEARY P, 1975, INT S EV NEW DRUGS C
[10]  
DECLERC GE, 1994, INT CLIN PSYCHOPHARM, V9, P138